Shots:

• SIGA to receive $12.4M as upfront with total value $19.5M to support clinical & regulatory activities of TPOXX (tecovirimat) in its evaluation as post-exposure prophylactic to treat smallpox symptomatic infection and patients with known smallpox exposure with no developed symptoms for smallpox
• The expanded indication of TPOXX provides flexibility to deliver TPOXX to those who might benefit from treatment during a potential outbreak. Additionally- SIGA is also working with U.S. Army Medical Research Institute of Infectious Disease on animal studies to evaluate TPOXX as PEP for smallpox
• TPOXX (PO- IV) is an anti-viral therapy- indicated to treat smallpox to mitigate the impact of a potential outbreak or bioterror attack and its oral formulation has received FDA’s Approval on Jul 13- 2018

Click here to read full press release/ article | Ref: SIGA | Image: EC-Council